[go: up one dir, main page]

LT3045474T - Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija - Google Patents

Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija

Info

Publication number
LT3045474T
LT3045474T LTEP16155009.0T LT16155009T LT3045474T LT 3045474 T LT3045474 T LT 3045474T LT 16155009 T LT16155009 T LT 16155009T LT 3045474 T LT3045474 T LT 3045474T
Authority
LT
Lithuania
Prior art keywords
treatment
therapeutic agents
cell proliferation
diseases associated
undesirable cell
Prior art date
Application number
LTEP16155009.0T
Other languages
English (en)
Inventor
Joan Seoane Suarez
Silvia PEÑUELAS PRIETO
José BASELGA TORRES
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Fundació Privada Institut d'Investigació Oncologica de Vall d'Hebron
Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avancats, Fundació Privada Institut d'Investigació Oncologica de Vall d'Hebron, Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Publication of LT3045474T publication Critical patent/LT3045474T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
LTEP16155009.0T 2009-04-03 2010-04-06 Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija LT3045474T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.

Publications (1)

Publication Number Publication Date
LT3045474T true LT3045474T (lt) 2021-05-10

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16155009.0T LT3045474T (lt) 2009-04-03 2010-04-06 Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija

Country Status (24)

Country Link
US (4) US10100112B2 (lt)
EP (2) EP2414394A2 (lt)
JP (5) JP6207836B2 (lt)
KR (6) KR102373754B1 (lt)
CN (2) CN102574918A (lt)
AU (1) AU2010233791B2 (lt)
BR (1) BRPI1015369A2 (lt)
CA (1) CA2757680C (lt)
CY (1) CY1124148T1 (lt)
DK (1) DK3045474T3 (lt)
EA (1) EA201101450A1 (lt)
ES (2) ES2363358B1 (lt)
HR (1) HRP20210352T1 (lt)
HU (1) HUE054196T2 (lt)
IL (1) IL215467A (lt)
LT (1) LT3045474T (lt)
MX (1) MX336903B (lt)
PL (1) PL3045474T3 (lt)
PT (1) PT3045474T (lt)
SG (2) SG175032A1 (lt)
SI (1) SI3045474T1 (lt)
SM (1) SMT202100153T1 (lt)
WO (1) WO2010115868A2 (lt)
ZA (1) ZA201107215B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2686093T3 (es) * 2005-07-19 2018-10-16 Stemgen S.P.A. Inhibición del potencial tumorigénico de células madre tumorales por BMP-4
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
WO2015136557A2 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
KR102503476B1 (ko) * 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
EP3191129A4 (en) * 2014-09-10 2018-03-14 The Regents of The University of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
AU2017381585B2 (en) 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
EP3794031A2 (en) * 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof
US20210253691A1 (en) * 2018-06-18 2021-08-19 Medimmune Limited Methods for improving response to anti-lif antibody treatment in individuals with cancer
US20210187106A1 (en) * 2018-06-18 2021-06-24 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
MX2021012163A (es) * 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
NZ227332A (en) 1987-12-15 1991-08-27 Gene Shears Pty Ltd Ribozymes, production and use
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DE60040651D1 (de) * 1999-02-12 2008-12-11 Emd Serono Res Ct Inc Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
JPWO2005116204A1 (ja) * 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
MX2011002082A (es) * 2008-08-29 2011-06-20 Genentech Inc Diagnostico y tratamientos para los tumores independientes del vegf.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof

Also Published As

Publication number Publication date
JP7197665B2 (ja) 2022-12-27
JP2019006784A (ja) 2019-01-17
KR20200078668A (ko) 2020-07-01
CY1124148T1 (el) 2022-05-27
ES2864639T3 (es) 2021-10-14
US11999782B2 (en) 2024-06-04
KR20220035978A (ko) 2022-03-22
IL215467A (en) 2016-06-30
SI3045474T1 (sl) 2021-07-30
BRPI1015369A2 (pt) 2021-06-29
PL3045474T3 (pl) 2021-08-09
KR20170121319A (ko) 2017-11-01
CN107964043A (zh) 2018-04-27
JP2020090522A (ja) 2020-06-11
SG10202010568RA (en) 2020-11-27
WO2010115868A2 (en) 2010-10-14
ES2363358B1 (es) 2012-06-21
IL215467A0 (en) 2011-12-29
JP2012522756A (ja) 2012-09-27
JP6207836B2 (ja) 2017-10-04
HUE054196T2 (hu) 2021-08-30
PT3045474T (pt) 2021-03-22
KR20120100703A (ko) 2012-09-12
KR20190093691A (ko) 2019-08-09
US20200385455A1 (en) 2020-12-10
US10100112B2 (en) 2018-10-16
AU2010233791B2 (en) 2016-01-21
CA2757680C (en) 2021-11-02
CN102574918A (zh) 2012-07-11
EA201101450A1 (ru) 2012-04-30
US20190211095A1 (en) 2019-07-11
AU2010233791A1 (en) 2011-11-03
SG175032A1 (en) 2011-11-28
HRP20210352T1 (hr) 2021-05-28
EP3045474A2 (en) 2016-07-20
EP3045474A3 (en) 2016-09-28
MX336903B (es) 2016-02-04
JP2022031742A (ja) 2022-02-22
WO2010115868A3 (en) 2011-02-03
DK3045474T3 (da) 2021-03-22
EP3045474B1 (en) 2021-01-13
JP2016040255A (ja) 2016-03-24
KR102373754B1 (ko) 2022-03-15
CA2757680A1 (en) 2010-10-14
ZA201107215B (en) 2012-12-27
US20240400667A1 (en) 2024-12-05
MX2011010425A (es) 2012-03-06
SMT202100153T1 (it) 2021-05-07
US20120114671A1 (en) 2012-05-10
EP2414394A2 (en) 2012-02-08
KR20180079470A (ko) 2018-07-10
ES2363358A1 (es) 2011-08-01

Similar Documents

Publication Publication Date Title
LT3045474T (lt) Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HRP20180575T1 (hr) Cervikalni jastuk za liječenje bolesti vratne kralježnice
IL200368A0 (en) Treatment of diseases characterized by inflammation
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
EP2623494A4 (en) MEDICINE FOR THE TREATMENT OF EYE DISEASES
PT2525796T (pt) Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA200905364B (en) Treatment of diseases characterized by inflammation
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
PL2003978T3 (pl) Terapia komórkami allogenicznymi do leczenia oportunistycznego zakażenia
IL213607A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
GB201202095D0 (en) Topical medicament for the treatment of psoriasis
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
SMT201600479B (it) Nuove soluzioni terapeutiche per il trattamento di condizioni neuroinfiammatorie
HK1158954A1 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
IT1398032B1 (it) Transferrina per il trattamento di malattie autoimmuni.
EP2701702A4 (en) OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISEASES
IT1406405B1 (it) Molecole peptidiche per il trattamento di patologie mitocondriali
GB0901727D0 (en) The treatment of ophthalmic diseases